Michael Bloch, MD
Internal Medicine · Reno, NVNPI 1508970195
Payments from drug & device makers
Across 563 payments — averaging $1189.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$187K
- Amgen$167K
- Johnson & Johnson$105K
- Recor Medical Inc$82K
- Idorsia Pharmaceuticals US Inc$33K
- Esperion Therapeutics, Inc.$29K
- plus $67K from 13 others
What the payments were for
- Consulting fees$122,73526%
- Speaking & faculty fees$246,96652%
- Travel & lodging$94,29820%
- Food & beverage$10,9252%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 203 | $186,741 |
| Amgen | 44 | $167,049 |
| Johnson & Johnson(2 entities) | 130 | $104,712 |
| Recor Medical Inc | 56 | $81,960 |
| Idorsia Pharmaceuticals US Inc | 24 | $32,553 |
| Esperion Therapeutics, Inc. | 33 | $29,449 |
| Corcept Therapeutics | 23 | $21,492 |
| Novartis | 15 | $15,012 |
| AstraZeneca | 1 | $8,679 |
| E.r. Squibb & Sons, L.L.C. | 2 | $7,488 |
| Amarin Pharma, Inc. | 9 | $5,231 |
| Boston Scientific | 4 | $4,310 |
| Vifor Pharma, Inc. | 7 | $3,678 |
| Boehringer Ingelheim | 3 | $747 |
| Regeneron Healthcare Solutions, Inc. | 5 | $312 |
| Regeneron | 1 | $85 |
| Biogen | 1 | $59 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$97,447
- SYMPLICITY G3$75,650
- Paradise Ultrasound Renal Denervation System$33,992
- NEXLIZET$28,857
- NEXLETOL$28,857
- Tryvio$23,339
- Repatha$21,374
- Korlym$21,070
- LEQVIO$13,222
- APROCITENTAN$8,747
- PARADISE RENAL DENERVATION SYSTEM$7,173
- Vascepa$4,999
- GENERAL - THERAPIES$4,183
- Veltassa$3,579
- ENTRESTO$239
- PRALUENT$219
- WATCHMAN Access System$127
How this compares
$669,588 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 145 | $174,044 |
| XareltoRivaroxaban | 112 | $96,306 |
| EliquisApixaban | 63 | $75,119 |
| Praluent PenAlirocumab | 44 | $43,281 |
| JardianceEmpagliflozin | 23 | $28,886 |
| NexlizetBempedoic Acid/Ezetimibe | 22 | $20,971 |
| TrulicityDulaglutide | 15 | $20,182 |
| MounjaroTirzepatide | 11 | $15,774 |
| NexletolBempedoic Acid | 18 | $14,013 |
| Icosapent Ethyl | 14 | $6,154 |
| Ezetimibe | 125 | $2,908 |
| Rosuvastatin Calcium | 149 | $1,890 |
| Telmisartan | 51 | $1,821 |
| Atorvastatin Calcium | 109 | $1,765 |
| Warfarin Sodium | 104 | $1,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $104,712 | $96,306112 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $29,449 | $34,98440 claims |
| Boehringer IngelheimJardiance | $747 | $28,88623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Reno
- Steven ZellReno$25K
- Darin BrimhallLas Vegas$39.7M
- Alton WaltersLas Vegas$8.9M
- Michael JacobsLas Vegas$8.1M
- Nirupa PaulrajLas Vegas$5.8M
- Atoya AdamsLas Vegas$5.4M
- Roger EstevezLas Vegas$3.7M
- Syed PervaizLas Vegas$3.1M
- Marigene Salazar SharmaHenderson$2.5M
- Mavis MatsumotoHenderson$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.